Pamidronate Disodium Injection Shortage
Last Updated: May 2, 2024
Status: Current
Products Affected - Description
-
- Pamidronate disodium injection, Mylan Institutional (Viatris), 3 mg/mL, 10 mL vial, 1 count, NDC 67457-0430-10
- Pamidronate disodium injection, Mylan Institutional (Viatris), 9 mg/mL, 10 mL vial, 1 count, NDC 67457-0446-10
- Pamidronate disodium injection, Pfizer, 3 mg/mL, 10 mL vial, 1 count, NDC 61703-0324-18
- Pamidronate disodium injection, Pfizer, 6 mg/mL, 10 mL vial, 1 count, NDC 61703-0325-18
Reason for the Shortage
-
- Areva is not currently marketing pamidronate disodium injection.
- Pfizer has pamidronate disodium injection on shortage due to manufacturing delays.
- Viatris did not provide a reason for the shortage.
Available Products
-
- Pamidronate disodium injection, Pfizer, 9 mg/mL, 10 mL vial, 1 count, NDC 61703-0326-18
Estimated Resupply Dates
-
- Pfizer has pamidronate disodium 3 mg/mL 10 mL vials and 6 mg/mL 10 mL vials on back order and the company estimates a release date of June 2024 for the 3 mg/mL 10 mL vials and September 2024 for the 6 mg/mL 10 mL vials.
- Viatris has pamidronate disodium 3 mg/mL 10 mL vials and 9 mg/mL 10 mL vials on back order and the company estimates a release date of early-May 2024.
Updated
Updated May 2, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 24, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.